25 August 2020Big PharmaRobert Stephen and Gareth Morgan
Why Santen ends Neurim-style SPCs
The July 9 Santen decision ( C-673/18) from the Court of Justice of the European Union (CJEU) resolves the issues that arose from the earlier Neurim decision ( C-130/11) issued by the same court. Essentially, and unusually, the CJEU reversed its own earlier decision.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
10 March 2026 UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.
11 February 2026 Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.
